
Proposed Acquisition of ResApp Health by Pfizer Australia Holdings Pty Limited, a wholly-owned subsidiary of Pfizer Inc, for $0.208 cash per share by scheme of arrangement.
Your Vote is Important
Your Directors unanimously recommend that you vote in favour of the Scheme, in the absence of a Superior Proposal and subject to the Independent Expert continuing to conclude that the Scheme is in the best interests of ResApp Health Shareholders.
The Independent Expert has concluded that the Scheme is in your best interests, in the absence of a superior proposal.
Scheme Announcements
For a full list of company announcements, visit the ASX website.
16 August 2022
8 August 2022
3 August 2022
20 July 2022
18 July 2022
15 July 2022
30 June 2022
21 June 2022
14 June 2022
11 April 2022